Print Email Facebook Twitter Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: Antiangiogenic properties of a new class of antitumor agents Title Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: Antiangiogenic properties of a new class of antitumor agents Author Zerp, S.F. Vink, S.R. Ruiter, G.A. Koolwijk, P. Peters, E. van der Luit, A.H. de Jong, D. Budde, M. Bartelink, H. van Blitterswijk, W.J. Verheij, M. TNO Kwaliteit van Leven Publication year 2008 Abstract Synthetic alkylphospholipids (APLs), such as edelfosine, miltefosine and perifosine, constitute a new class of antineoplastic compounds with various clinical applications. Here we have evaluated the antiangiogenic properties of APLs. The sensitivity of three types of vascular endothelial cells (ECs) (bovine aortic ECs, human umbilical vein ECs and human microvascular ECs) to APL-induced apoptosis was dependent on the proliferative status of these cells and correlated with the cellular drug incorporation. Although confluent, nondividing ECs failed to undergo apoptosis, proliferating ECs showed a 3-4-fold higher uptake and significant levels of apoptosis after APL treatment. These findings raised the question of whether APLs interfere with new blood vessel formation. To test the antiangiogenic properties in vitro, we studied the effect of APLs using two different experimental models. The first one tested the ability of human microvascular ECs to invade a three-dimensional human fibrin matrix and form capillary-like tubular networks. In the second model, bovine aortic ECs were grown in a collagen gel sandwich to allow tube formation. We found that all three APLs interfered with endothelial tube formation in a dose-dependent manner, with a more than 50% reduction at 25 μmol/l. Interference with the angiogenic process represents a novel mode of action of APLs and might significantly contribute to the antitumor effect of these compounds. © 2008 Lippincott Williams & Wilkins, Inc. Chemicals / CAS: collagen, 9007-34-5; edelfosine, 65492-82-2; fibrin, 9001-31-4; miltefosine, 58066-85-6; perifosine, 157716-52-4; Angiogenesis Inhibitors; Antineoplastic Agents; D 21266; edelfosine, 65492-82-2; Indicators and Reagents; Phosphodiesterase Inhibitors; Phospholipid Ethers; Phospholipids; Phosphorylcholine, 107-73-3 Subject Healthy for LifeHealthHealthy LivingAlkylphospholipidsAngiogenesisApoptosisEndothelial cellsIn Vitroangiogenesis inhibitorantineoplastic agentcollagenedelfosinefibrinmiltefosineperifosinephospholipid derivativeangiogenesisantiangiogenic activityantineoplastic activityaortaapoptosisstatistical significanceumbilical veinvascular endotheliumAlkylationAngiogenesis InhibitorsAnimalsAntineoplastic AgentsApoptosisCapillariesCattleCell Line, TumorCells, CulturedDose-Response Relationship, DrugEndothelial CellsEndothelium, VascularHumansIndicators and ReagentsPhosphodiesterase InhibitorsPhospholipid EthersPhospholipidsPhosphorylcholine To reference this document use: http://resolver.tudelft.nl/uuid:8c773f33-e2ff-4e60-ac97-58ea8c6bf3d2 DOI https://doi.org/10.1097/cad.0b013e3282f16d36 TNO identifier 240599 ISSN 0959-4973 Source Anti-Cancer Drugs, 19 (1), 65-75 Document type article Files To receive the publication files, please send an e-mail request to TNO Library.